RECRUITING

Long-Term Follow-Up of Recipient of Gene Transfer Research

Talk to us

Conditions

Retroviridae InfectionsCancerReplication-Competent RetrovirusRCRGene transfer therapyRegistryMedical information databaseVector or vector-treated cellsBlood drawComputed tomographyCTQuestionnairesSurveysGene Transfer ResearchNational Gene Vector Biorepository and Coordinating CenterNGVB

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

The goal of this clinical research study is to collect information about the long-term safety of gene transfer therapy. This study is also designed to create a database of medical information about patients who have received gene transfer therapy, in order for researchers to track and review the long-term safety and any effects (good or bad) of gene transfer therapy.

Official Title

Long-Term Follow-Up Study of Recipients of Gene Transfer Research Protocols

Quick Facts

Study Start:2011-12-09
Study Completion:2027-12-31
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT01492036

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:Not specified
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:Yes
Standard Ages:CHILD, ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. 1. Patient or patient's legal representative(s) provided written informed consent to participate in a gene transfer study at the University of Texas MD Anderson Cancer Center (MD Anderson).
  2. 2. Patient will receive vector or vector-treated cells at MD Anderson.
  3. 3. Patient or patient's legal representative(s) is/are able to provide written informed consent to participate in this long-term follow-up protocol for gene transfer participants for up to 15 years following administration of gene therapy product.
  4. 4. Agree to allow clinical samples to be collected and stored at MD Anderson and/or at a NIH designated facility such as the NGVB.
  1. Pregnancy or breastfeeding
  2. Severe psychiatric disorders
  3. Active substance abuse
  4. Unstable medical conditions
  5. Inability to comply with study requirements

Contacts and Locations

Study Contact

Partow Kebriaei, MD
CONTACT
713-792-8750
pkebriae@mdanderson.org

Principal Investigator

Partow Kebriaei, MD
PRINCIPAL_INVESTIGATOR
M.D. Anderson Cancer Center

Study Locations (Sites)

University of Texas MD Anderson Cancer Center
Houston, Texas, 77030
United States

Collaborators and Investigators

Sponsor: M.D. Anderson Cancer Center

  • Partow Kebriaei, MD, PRINCIPAL_INVESTIGATOR, M.D. Anderson Cancer Center

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2011-12-09
Study Completion Date2027-12-31

Study Record Updates

Study Start Date2011-12-09
Study Completion Date2027-12-31

Terms related to this study

Keywords Provided by Researchers

  • Replication-Competent Retrovirus
  • RCR
  • Gene transfer therapy
  • Registry
  • Medical information database
  • Vector or vector-treated cells
  • Blood draw
  • Computed tomography
  • CT
  • Questionnaires
  • Surveys
  • Gene Transfer Research
  • National Gene Vector Biorepository and Coordinating Center
  • NGVB

Additional Relevant MeSH Terms

  • Retroviridae Infections
  • Cancer